Photobiomodulation: Research Overview
What photobiomodulation is, how it is proposed to work, where human trials and guidelines exist, where they do not, and how it differs from wellness-device marketing.
Content last updated . This page has not been medically reviewed.
Keep four things apart
| Term | What it means | Example of a mistake |
|---|---|---|
| Mechanism | A proposed way light could act on cells | "It boosts mitochondria, so it treats my condition" |
| Technology | The light source and its output | Treating all red lights as the same |
| Intervention | A specific use, in a specific group, for a specific outcome | Generalizing from mouth sores in cancer care to "healing" |
| Product | One device with one cleared or uncleared status | Applying one device's clearance to a similar-looking one |
The proposed mechanism (preclinical)
A 2026 review describes the leading idea: red and near-infrared light acts on an enzyme in mitochondria (cytochrome c oxidase), which may release nitric oxide, raise ATP production and trigger small, controlled bursts of reactive oxygen species. The same review says these effects follow a "biphasic" dose-response (too little or too much light may do less than a middle amount) and that tissue optical properties differ between animal models and humans, which adds variability to clinical results. [1] Those findings come largely from cells and animals, so this page treats the mechanism as preclinical. A mechanism does not prove benefit; see Mechanism vs Demonstrated Benefit.Where human evidence is strongest
- Preventing mouth sores (oral mucositis) in specific cancer treatments. A systematic review and guideline from the supportive-care cancer societies (MASCC/ISOO) recommends PBM for preventing oral mucositis in people having stem-cell transplantation or head-and-neck radiotherapy, with or without chemotherapy. It found no guideline possible for treating established mouth sores or for chemotherapy-related mucositis because of inadequate evidence. [2] An overview of 16 systematic reviews found most favored PBM, with moderate confidence in most. [3] Label: established for these settings, delivered by trained clinicians using specific protocols.
- Some musculoskeletal pain. Reviews of randomized trials of low-level laser therapy found reduced pain in knee osteoarthritis and in lower-limb tendinopathy and plantar fasciitis, with wide uncertainty. [4][5] An AHRQ review rated evidence for low-level laser therapy as moderate for chronic neck pain at short term. [6] Label: promising but limited.
Several of these reviews include authors linked to a laser-therapy association, which is a disclosed potential conflict of interest. [4]
Where evidence is thin or mixed
Results for acne, diabetic foot ulcers, fibromyalgia, hair loss, skin appearance and brain or mood outcomes vary in quality and size. They are covered with sources on the evidence-by-condition page. A small trial of a wearable head-worn near-infrared device in 48 people with major depression found no difference from sham in depression scores, though sleep-quality scores improved more with the active device; the authors said the low dosing may have been insufficient and that the trial was short and small. [7] That is insufficient evidence for depression.Frequently asked questions
Is photobiomodulation the same as red light therapy?
Red light therapy is one common name for it, but PBM also covers near-infrared light and lasers. Names do not tell you the device, output or evidence. Each use has to be judged separately.
Does PBM have any established medical use?
In cancer supportive care, an expert guideline recommends it for preventing oral mucositis in specific treatment settings. [2] That does not extend to other conditions.
Is there proof it works at the cellular level?
Laboratory studies describe mitochondrial effects, but these are preclinical, and tissue depth and dose in humans add uncertainty. [1]
Does an FDA-cleared light mean it works for everything?
No. Clearance applies to a named device and its stated indication. [9][10]
More details: evidence, limits and cautions
The details behind this page: cautions, limits of the evidence and where sources disagree. Open any note to read it.
How to read the evidence labels
Labels used on this page: approved medicine or cleared device (regulator and indication named), established, promising but limited, mixed, insufficient evidence, preclinical (cells/animals only), marketing claim.
Regulation: devices, not "light therapy" in general
- Infrared lamps intended to provide topical heating are a Class II device type, and therapeutic heating lamps are exempt from premarket notification. [8]
- A laser comb cleared for promoting hair growth in men with a specific pattern of androgenetic alopecia is a Class II 510(k) product code. [9]
- Non-thermal laser devices for adjunctive use in pain therapy have their own Class II product code. [10]
- LEDs are described by the FDA as different from laser diodes and not subject to the federal laser product performance standard. [11]
A clearance covers the named device and its stated use. It does not validate other devices or other claims. Many consumer "red light" products are sold under general-wellness positioning; see Device-Specific Evidence for Light Therapy Products. Rules in other countries were not verified. This is not legal advice.
Safety and who should check first
References
- Ahmed R, et al. Photobiomodulation for skeletal muscle regeneration: mechanisms, dosimetry, and translational challenges. Front Bioeng Biotechnol. 2026. Read 2026-10-22.
- Zadik Y, et al. Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer. 2019. Read 2026-10-22.
- Vieira Nascimento M, et al. Management of cancer therapy-induced oral mucositis using photobiomodulation therapy: an overview of systematic reviews. Photobiomodul Photomed Laser Surg. 2023. Read 2026-10-22.
- Stausholm MB, et al. Efficacy of low-level laser therapy on pain and disability in knee osteoarthritis. BMJ Open. 2019. Read 2026-10-22.
- Naterstad IF, et al. Efficacy of low-level laser therapy in patients with lower extremity tendinopathy or plantar fasciitis. BMJ Open. 2022. Read 2026-10-22.
- Skelly AC, et al. Noninvasive Nonpharmacological Treatment for Chronic Pain: A Systematic Review Update. AHRQ Comparative Effectiveness Reviews. 2020. Read 2026-10-22.
- Guu TW, et al. Wearable, self-administered transcranial photobiomodulation for major depressive disorder and sleep. J Affect Disord. 2025. Read 2026-10-22.
- U.S. Food and Drug Administration, eCFR. 21 CFR 890.5500, Infrared lamp. Read 2026-10-22.
- U.S. Food and Drug Administration. Product Classification: laser, comb, hair (OAP). Read 2026-10-22.
- U.S. Food and Drug Administration. Product Classification: powered light based laser non-thermal instrument for adjunctive use in pain therapy (NHN). Read 2026-10-22.
- U.S. Food and Drug Administration. Laser Products and Instruments. Read 2026-10-22.
- National Center for Complementary and Integrative Health. Seasonal Affective Disorder. Read 2026-10-22.